Press Resease

Breast Cancer Liquid Biopsy Market by Biomarker (Circulating Tumor Cells (CTCs), Cell-free DNA (cfDNA), Extracellular Vesicles (EVs), and Other Circulating Biomarkers) and End User (Reference Laboratories, Hospitals and Physician Laboratories, and Other End Users): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024

Published Date: 29-Aug-2018 Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-3302 Status : Published

Global breast cancer liquid biopsy market expected to generate revenue of around USD 642.9 million by end of 2024, growing at a CAGR of around 22.9% between 2018 and 2024. Liquid biopsy assesses the presence of tumor cell-derived biomarkers such as cell-free DNA (cfDNA), circulating tumor cells, extracellular vesicles (exosomes) and their cargo, proteins, and circulating cell-free RNA (cfRNA).

Description

The report covers forecast and analysis for the breast cancer liquid biopsy market on a global and regional level. The study provides historic data from 2015 along with a forecast from 2018 to 2024 based on revenue (USD Million). The study includes drivers and restraints for the breast cancer liquid biopsy market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the breast cancer liquid biopsy market on a global as well as regional level.

In order to give the users of this report a comprehensive view of the breast cancer liquid biopsy market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein product segment is benchmarked based on their market size, growth rate, and general attractiveness.

Global Breast Cancer Liquid Biopsy Market

The report provides company market share analysis in order to give a broader overview of the key players in the breast cancer liquid biopsy market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the breast cancer liquid biopsy market on the global and regional basis. 

The study provides a decisive view on the breast cancer liquid biopsy market by segmenting the market based on biomarkers, end users, and regions. The segments have been analyzed based on present and future trends and the market is estimated from 2017 to 2024. The biomarker segment has been segmented into Circulating Tumor Cells (CTCs), Cell-free DNA (cfDNA), Extracellular Vesicles (EVs) and Other Circulating Biomarkers. Other circulating biomarkers include cell-free protein biomarkers and circulating RNA (ctRNA and cfRNA). Cell-free DNA segment holds the maximum share of the biomarker segment. Based on end user, breast cancer liquid biopsy market has been segmented into reference laboratories, hospitals and physician laboratories, other end users. Other end users include research institutes, academic research laboratories, pathology laboratories etc.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further bifurcation into major countries including the U.S., Canada, Germany, France, UK, China, Japan, India, and Brazil. This segmentation includes demand for pediatric medical devices based on individual segment and applications in all the regions and countries.

The report also includes detailed profiles of end players such as QIAGEN N.V., Roche Diagnostics, Bio-Rad Laboratories, Myriad Genetics, Menarini Silicon Biosystems, Illumina, Cynvenio Biosystems, Inc., Genomic Health, Inc., Thermo Fisher Scientific Inc., Fluxion Biosciences, Inc., Biodesix, Inc., Guardant Health, Inc., and Isogen Life Science B.V. among others.

This report segments the global Breast Cancer Liquid Biopsy Market as follows:

Global Breast Cancer Liquid Biopsy Market: By Biomarker

  • Circulating Tumor Cells (CTCs)
  • Cell-free DNA (cfDNA)
  • Extracellular Vesicles (EVs)
  • Other Circulating Biomarkers (ctRNA, cfRNA and cell free proteins)

Global Breast Cancer Liquid Biopsy Market: By End User

  • Reference Laboratories
  • Hospitals and Physician Laboratories
  • Other End Users

Global Breast Cancer Liquid Biopsy Market: By Region

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Breast Cancer Liquid Biopsy Market, 2017 - 2024 (USD Million)
    • 2.2. Global Breast Cancer Liquid Biopsy Market : Snapshot
  •  
  • Chapter 3. Breast Cancer Liquid Biopsy - Market Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global Breast Cancer Liquid Biopsy Market drivers: Impact analysis
      • 3.2.2. Rise in prevalence of breast cancer worldwide
      • 3.2.3. Preference for noninvasive procedure
    • 3.3. Market Restraints
      • 3.3.1. High cost
      • 3.3.2. Lack of trained professionals
    • 3.4. Opportunities
      • 3.4.1. Favorable governments policies and fund for research and development
    • 3.5. Porter's five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by biomarker segment
      • 3.6.2. Market attractiveness analysis, by end user segment
      • 3.6.3. Market attractiveness analysis, by regional segment
  •  
  • Chapter 4. Global Breast Cancer Liquid Biopsy Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Breast Cancer Liquid Biopsy Market: company market share, 2017
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Product Launch
      • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
      • 4.2.4. Research and Development, Regional Expansion
  •  
  • Chapter 5. Global Breast Cancer Liquid Biopsy Market - Biomarker Segment Analysis
    • 5.1. Global Breast Cancer Liquid Biopsy Market: Biomarker overview
      • 5.1.1. Global Breast Cancer Liquid Biopsy Market revenue share, by Biomarker, 2017 and 2024
    • 5.2. Circulating Tumor Cells (CTCs)
      • 5.2.1. Global Breast Cancer Liquid Biopsy Market for Circulating Tumor Cells (CTCs), 2017 - 2024 (USD Million)
    • 5.3. Cell-free DNA (cfDNA)
      • 5.3.1. Global Breast Cancer Liquid Biopsy Market for Cell-free DNA (cfDNA), 2017 - 2024 (USD Million)
    • 5.4. Extracellular Vesicles (EVs)
      • 5.4.1. Global Breast Cancer Liquid Biopsy Market for Extracellular Vesicles (EVs), 2017 - 2024 (USD Million)
    • 5.5. Other Circulating Biomarkers
      • 5.5.1. Global Breast Cancer Liquid Biopsy Market for Other Circulating Biomarkers, 2017 - 2024 (USD Million)
  •  
  • Chapter 6. Global Breast Cancer Liquid Biopsy Market - End-User Segment Analysis
    • 6.1. Global Breast Cancer Liquid Biopsy Market: End User overview
      • 6.1.1. Global Breast Cancer Liquid Biopsy Market revenue share, by End User, 2017 and 2024
    • 6.2. Reference Laboratories
      • 6.2.1. Global Breast Cancer Liquid Biopsy Market for Reference Laboratories, 2017 - 2024 (USD Million)
    • 6.3. Hospitals and Physician Laboratories
      • 6.3.1. Global Breast Cancer Liquid Biopsy Market for Hospitals and Physician Laboratories, 2017 - 2024 (USD Million)
    • 6.4. Other End Users
      • 6.4.1. Global Breast Cancer Liquid Biopsy Market for Other End Users, 2017 - 2024 (USD Million)
  •  
  • Chapter 7. Global Breast Cancer Liquid Biopsy Market - Regional Segment Analysis
    • 7.1. Global Breast Cancer Liquid Biopsy Market: Regional overview
      • 7.1.1. Global Breast Cancer Liquid Biopsy Market revenue share, by region, 2017 and 2024
    • 7.2. North America
      • 7.2.1. North America Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
      • 7.2.2. North America Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.2.3. U.S.
        • 7.2.3.1. U.S. Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.2.3.2. U.S. Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.2.4. Canada
        • 7.2.4.1. Canada Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.2.4.2. Canada Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.2.5. Rest of North America
        • 7.2.5.1. Rest of North America Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.2.5.2. Rest of North America Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
    • 7.3. Europe
      • 7.3.1. Europe Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
      • 7.3.2. Europe Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.3.3. Germany
        • 7.3.3.1. Germany Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.3.3.2. Germany Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.3.4. U.K.
        • 7.3.4.1. U.K. Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.3.4.2. U.K. Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.3.5. France
        • 7.3.5.1. France Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.3.5.2. France Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.3.6. Italy
        • 7.3.6.1. Italy Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.3.6.2. Italy Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.3.7. Spain
        • 7.3.7.1. Spain Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.3.7.2. Spain Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.3.8. Russia
        • 7.3.8.1. Russia Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.3.8.2. Russia Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.3.9. Rest of Europe
        • 7.3.9.1. Rest of Europe Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.3.9.2. Rest of Europe Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
      • 7.4.2. Asia Pacific Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.4.3. China
        • 7.4.3.1. China Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.4.3.2. China Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.4.4. Japan
        • 7.4.4.1. Japan Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.4.4.2. Japan Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.4.5. India
        • 7.4.5.1. India Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.4.5.2. India Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.4.6. Australia
        • 7.4.6.1. Australia Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.4.6.2. Australia Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.4.7. Rest of Asia Pacific
        • 7.4.7.1. Rest of Asia Pacific Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.4.7.2. Rest of Asia Pacific Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
    • 7.5. Latin America
      • 7.5.1. Latin America Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
      • 7.5.2. Latin America Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.5.3. Brazil
        • 7.5.3.1. Brazil Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.5.3.2. Brazil Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.5.4. Mexico
        • 7.5.4.1. Mexico Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.5.4.2. Mexico Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.5.5. Argentina
        • 7.5.5.1. Argentina Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.5.5.2. Argentina Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.5.6. Rest of Latin America
        • 7.5.6.1. Rest of Latin America Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.5.6.2. Rest of Latin America Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
    • 7.6. Middle East and Africa
      • 7.6.1. Middle East and Africa Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
      • 7.6.2. Middle East and Africa Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.6.3. Saudi Arabia
        • 7.6.3.1. Saudi Arabia Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.6.3.2. Saudi Arabia Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.6.4. UAE
        • 7.6.4.1. UAE Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.6.4.2. UAE Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.6.5. South Africa
        • 7.6.5.1. South Africa Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.6.5.2. South Africa Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.6.6. Qatar
        • 7.6.6.1. Qatar Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.6.6.2. Qatar Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.6.7. Rest of Middle East and Africa
        • 7.6.7.1. Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market revenue, by Biomarker, 2017 - 2024 (USD Million)
        • 7.6.7.2. Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market revenue, by End User, 2017 - 2024 (USD Million)
  •  
  • Chapter 8. Company Profile
    • 8.1. QIAGEN N.V.
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Therapy portfolio
      • 8.1.4. Business strategy
      • 8.1.5. Recent developments
    • 8.2. Roche Diagnostics
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Therapy portfolio
      • 8.2.4. Business strategy
      • 8.2.5. Recent developments
    • 8.3. Bio-Rad Laboratories
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Therapy portfolio
      • 8.3.4. Business strategy
      • 8.3.5. Recent developments
    • 8.4. Myriad Genetics
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Therapy portfolio
      • 8.4.4. Business strategy
      • 8.4.5. Recent developments
    • 8.5. Menarini Silicon Biosystems
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Therapy portfolio
      • 8.5.4. Business strategy
      • 8.5.5. Recent developments
    • 8.6. Illumina
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Therapy portfolio
      • 8.6.4. Business strategy
      • 8.6.5. Recent developments
    • 8.7. Cynvenio Biosystems, Inc.
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Therapy portfolio
      • 8.7.4. Business strategy
      • 8.7.5. Recent developments
    • 8.8. Genomic Health, Inc.
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Therapy portfolio
      • 8.8.4. Business strategy
      • 8.8.5. Recent developments
    • 8.9. Thermo Fisher Scientific Inc.
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Therapy portfolio
      • 8.9.4. Business strategy
      • 8.9.5. Recent developments
    • 8.10. Fluxion Biosciences, Inc.
      • 8.10.1. Overview
      • 8.10.2. Financials
      • 8.10.3. Therapy portfolio
      • 8.10.4. Business strategy
      • 8.10.5. Recent developments
    • 8.11. Biodesix, Inc.
      • 8.11.1. Overview
      • 8.11.2. Financials
      • 8.11.3. Therapy portfolio
      • 8.11.4. Business strategy
      • 8.11.5. Recent developments
    • 8.12. Guardant Health, Inc.
      • 8.12.1. Overview
      • 8.12.2. Financials
      • 8.12.3. Therapy portfolio
      • 8.12.4. Business strategy
      • 8.12.5. Recent developments
    • 8.13. Isogen Life Science B.V.
      • 8.13.1. Overview
      • 8.13.2. Financials
      • 8.13.3. Therapy portfolio
      • 8.13.4. Business strategy
      • 8.13.5. Recent developments

Methodology

Free Analysis

A liquid biopsy is an important diagnostic tool for diseases such as cancer and it uses non-solid biological tissue for sampling and analysis. As liquid biopsy is a noninvasive alternative procedure that makes use of blood as a sample, it is preferred more than surgical tissue biopsy. The procedure has various advantages over traditional surgical biopsy. It is quicker and tolerable in patients as it is noninvasive. Cancer can be detected well before the onset of clinical symptoms which would help restrict disease progression and monitor treatment efficacy using liquid biopsy. 

Cancer is caused due to single or multiple genetic mutations. Many tumor cells release their constituents in the blood. These constituents act as a biomarker and are used in the detection of the presence of tumor cells. Various biomarkers that are used as a tool for detection of cancer are circulating tumor cells (CTC), cell-free DNA (cfDNA) derived from tumor cells, and extracellular vesicles. RNA based biomarkers and other proteins originated from tumor cells are also used for diagnosis. Liquid biopsy detects the presence of such biomarkers in the blood sample. Thus these biomarkers offer a valuable tool for detection of mutations in cancerous cells.

Global Breast Cancer Liquid Biopsy Market

Though liquid biopsy offers advantages over surgical biopsy, the research is still ongoing. Amount of cell-free DNA greatly varies in healthy individuals and cancer patients. Thus measuring the amount of cfDNA helps to detect the presence of tumor cells. But certain conditions like autoimmune disorders, chronic inflammation exhibit higher levels of cfDNA, which may cause ambiguity. Thus in such cases use of cancer-specific biomarkers such as CTC and EV is more important. Thus liquid biopsy is a valuable means for the early detection of cancer. Liquid biopsy also helps to monitor disease progression based on heterogeneity of tumor cells in advanced stages of cancer. Globally, breast cancer is one of the major malignancies and liquid biopsy acts as an immensely important early cancer diagnosis tool.

Breast cancer is the most common type of cancer among women and is the second most common type of cancer worldwide. As per the World Cancer Research Fund International data, about 1.7 million new cases of breast cancer were diagnosed in 2012 which accounts almost 11.9% of all cancers. As per GLOBOCAN 2012 estimates for breast cancer, worldwide the incidence rates vary greatly, as 27 per 100,000 in Eastern Asia and Middle Africa, 92 in Northern America and 89.7 in Western Europe as per World Health Organization (WHO) estimates. Compared to the incidence rate, the mortality rate is less with 6 per 100,000 in Eastern Asia to 20 in Western Africa.

The rise in the prevalence of breast cancer worldwide drives the growth of breast cancer liquid biopsy market. Additionally increased awareness about cancer and preference for noninvasive test procedures help in the growth of breast cancer liquid biopsy market. Developed healthcare infrastructure and government funding for research and development are factors that boost the growth of this market in developed countries. Whereas increased disposable income and healthcare expenditure are also some of the factors driving the market growth in developing nations. Also initiatives by governments and other organizations working in the healthcare sector to curb cancer act as a golden opportunity for the key players in this market. Nevertheless, the high cost of test and lack of trained professionals can restrict the growth of global breast cancer liquid biopsy market.

The global breast cancer liquid biopsy market is segmented into biomarkers, end-user, and region. The biomarker segment has been classified into cell-free DNA (cfDNA), circulating tumor cells (CTCs), extracellular vesicles (EVs), and others. Other segment includes circulating biomarkers such as cell-free protein biomarkers and circulating RNA (ctRNA and cfRNA). Cell-free DNA segment holds a maximum share of the biomarker segment. End users of breast cancer liquid biopsy market are physician laboratories and hospitals, reference laboratories and other. Other end users include research institutes, pathology laboratories, academic research centers, etc.  

North America will be the dominant region during the forecast period. Developed healthcare infrastructure, the high prevalence of breast cancer, the presence of major key players in the region, and the availability of skilled manpower will boost the market in this region. Europe anticipates being the second largest market. The Asia Pacific will grow at the fastest rate over the forecast period. Increasing healthcare expenditure, awareness about cancer, and increased disposable income are the driving factors for the growth of the breast cancer liquid biopsy market in this region. Latin America market is projected to grow at a moderate rate during the forecast period. The Middle East and Africa are expected to experience noticeable growth in the years to come.
Some of the key players in breast cancer liquid biopsy market include QIAGEN N.V., Roche Diagnostics, Bio-Rad Laboratories, Myriad Genetics, Menarini Silicon Biosystems, Illumina, Cynvenio Biosystems, Inc., Genomic Health, Inc., Thermo Fisher Scientific Inc., Fluxion Biosciences, Inc., Biodesix, Inc., Guardant Health, Inc., and Isogen Life Science B.V., among others.

Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com